Physician profile
Mark Brannon
NPI 1194839985
$10,973.66
in general payments reported to CMS, 2019-2025
63 companies · $2,544 in 2025
The $2,544 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,910 · 2022: $3,137 · 2023: $2,803 · 2024: $581 · 2025: $2,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,431 · Consulting Fee: $1,800 · Education: $500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,431.13 |
| Consulting Fee | $1,800.00 |
| Education | $500.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $196.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,306.77 | 2021-2025 | |
| Janssen Biotech, INC. | $784.80 | 2021-2023 | Imbruvica, Erleada, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $679.93 | 2021-2024 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $645.77 | 2021-2025 | Enhertu, Tagrisso, Imfinzi |
| Seagen INC. | $560.18 | 2021-2023 | Padcev, Adcetris, Tukysa |
| Genzyme Corporation | $557.91 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $402.00 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $387.72 | 2021-2023 | Lumakras, Blincyto, Prolia |
| Lilly USA, LLC | $285.58 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $284.35 | 2021-2023 | Xtandi |
| Celgene Corporation | $262.01 | 2021-2023 | Pomalyst, Reblozyl |
| Incyte Corporation | $251.95 | 2021-2023 | Monjuvi, Pemazyre, Jakafi |
| Regeneron Healthcare Solutions, INC. | $245.35 | 2021-2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $245.10 | 2021-2023 | Ninlaro, Alunbrig |
| Glaxosmithkline, LLC. | $228.60 | 2021-2024 | Jemperli, Zejula |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.